*ST东洋(002086) - 2023 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2023 was CNY 437,233,445, a decrease of 30.52% compared to CNY 629,302,311 in 2022[22]. - The net profit attributable to shareholders for 2023 was CNY 1,749,600.27, compared to CNY 1,584,905.38 in 2022, reflecting an increase[22]. - The net profit after deducting non-recurring gains and losses was CNY 635,887,563, a decrease of 29.25% from CNY 898,841,849 in 2022[22]. - The net cash flow from operating activities was CNY 46,190,507.4, a decrease of 7.51% compared to CNY 42,962,176.4 in 2022[22]. - Basic and diluted earnings per share for 2023 were CNY 0.89, compared to a loss of CNY 2.10 in 2022[22]. - The company's total assets reached CNY 2,707,578,830, an increase of 35.22% compared to the previous year[24]. - The company's total revenue from processing services was CNY 89,550,255.11, a decrease of 25.21% compared to the previous year[64]. - The company's revenue from the mainland China market was CNY 245,419,092.16, a decrease of 41.91% compared to the previous year[64]. - The gross profit margin for the aquaculture industry was -83.86%, reflecting a significant decline of 7.15% year-on-year[65]. - The gross profit margin for the external diagnostic industry was 59.75%, down 5.96% from the previous year[65]. Business Operations - The company has not reported any changes in its main business operations since its listing[22]. - The company is focusing on the development of smart aquaculture technologies, aligning with national policies aimed at enhancing the fishing industry[36]. - The company is experiencing a shift from traditional extensive aquaculture to modern intensive and eco-friendly practices[37]. - The company is expanding its market presence both domestically and internationally, driven by increasing demand in the aquaculture sector[37]. - The company has established a comprehensive supply chain with a focus on product traceability to enhance food safety and meet consumer demand for high-quality seafood[38]. - The company has developed a research and promotion platform for breeding and seedling cultivation in collaboration with leading institutions, enhancing its technological capabilities[43]. - The company has achieved a leading position in the industry for sea cucumber and kelp breeding and farming technology[46]. - The company is actively expanding its market presence in Japan, South Korea, the United States, and the European Union[44]. - The company is committed to the dual-driven development of the marine and health industries, focusing on technological innovation and industry transformation[42]. Environmental and Compliance - The company emphasizes the risks associated with environmental pollution and natural disasters affecting its aquaculture operations[4]. - The company is committed to maintaining compliance with the Shenzhen Stock Exchange's disclosure requirements for the aquaculture industry[4]. - The company has implemented advanced environmental management practices and has not experienced any sudden environmental pollution incidents[185]. - The company strictly adheres to various environmental protection laws and standards, ensuring compliance in its operations[183]. - The company has established an ISO14001 environmental management system to enhance its environmental management capabilities and competitiveness[186]. - The company has established a monitoring system for pollutant discharge, which is subject to real-time supervision by environmental regulatory authorities[185]. - The company reported a total COD discharge of 9.66 tons, well within the regulatory limit of 12 tons[184]. - The company has committed to timely rectification of any governance issues identified during self-inspections as part of its compliance with governance action requirements[179]. Research and Development - The company is focusing on technological innovation in the marine industry and health sector, leveraging national and provincial research platforms to enhance its competitive edge[60]. - The company reported a research and development investment of ¥24,643,337.32 in 2023, a decrease of 11.08% compared to ¥27,712,739.62 in 2022[75]. - The number of R&D personnel increased by 4.17% to 75 in 2023, compared to 72 in 2022[75]. - The company is developing HPV high-risk subtype detection technology to improve cervical cancer screening accuracy and efficiency, aiming for early detection and treatment opportunities[73]. - The company is enhancing its capabilities in in vitro diagnostics and precision medicine, with over 200 reagent products, of which nearly 150 have been certified and launched[113]. Governance and Management - The company has a robust governance structure, ensuring independence from major shareholders and maintaining effective operational control[138]. - The company is committed to maintaining a robust governance structure with the recent board changes aimed at enhancing operational efficiency[143]. - The company reported a significant leadership change with the resignation of multiple board members on August 18, 2023, due to term expiration[143]. - The company is undergoing a board re-election process, with new members being elected on August 18, 2023, including Huang Zhi Hua as acting chairman and vice president[144]. - The company has a strong leadership team with a mix of experienced executives[157]. Market Trends and Future Outlook - The company anticipates that by 2025, the contribution rate of technological progress in fisheries will reach 67%[36]. - The company aims to leverage its existing research, technology, and resources to accelerate the development of in vitro diagnostics and precision medicine, targeting both domestic and international markets[106]. - The company plans to establish a dual business model focusing on marine and health industries, enhancing profitability and international competitiveness[107]. - The health industry is projected to grow significantly due to factors like population aging, urbanization, and increased health awareness, driving demand for diverse health services[106]. - The company is expected to leverage its new board composition to drive future growth and innovation in its product offerings[144]. Challenges and Risks - The company faces risks from disease outbreaks in aquaculture, with potential annual economic losses exceeding hundreds of millions due to disease spread[118]. - The company will implement measures to monitor and control pollution in aquaculture areas to mitigate environmental risks[119]. - The company recognizes the risk of natural disasters affecting aquaculture operations and will leverage its advantageous location to minimize potential losses[119]. - The company acknowledges the lag in domestic market marketing efforts and aims to enhance its sales network to improve performance[124]. - The company is facing foreign exchange risks due to the appreciation of the RMB, which could lead to increased costs and reduced gross margins in its processing business[126].